1-9 of 9
Oliver Hantschel
Close
Sort by
Journal Articles

BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib

Ariel Leyte-Vidal, Diego Garrido Ruiz, RosaAnna DeFilippis, Inga B Leske, Delphine Rea, Stacey Phan, Kaeli B Miller, Feifei Hu, Anjeli Mase, Yibing Shan, Oliver Hantschel, Matthew P Jacobson, Neil Shah
Journal: Blood
Blood blood.2023022538.
https://doi.org/10.1182/blood.2023022538
Published: 2024
Journal Articles

CDK6 degradation hits Ph + ALL hard

Oliver Hantschel
Journal: Blood
Blood (2020) 135 (18): 1512–1514.
https://doi.org/10.1182/blood.2020005136
Published: 2020
Journal Articles

Comprehensive Analysis of the Structural, Biochemical and Signaling Differences of the p210 and p185 Isoforms of Bcr-Abl in CML and B-ALL

Oliver Hantschel, PhD, Sina Reckel, Hamelin Romain, Florence Armand, Delphine Harduin, Shohei Koide, Volker Dötsch, Marc Moniatte
Journal: Blood
Blood (2016) 128 (22): 4238.
https://doi.org/10.1182/blood.V128.22.4238.4238
Published: 2016
Journal Articles

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases

Yashodhara Dasgupta, Mateusz Koptyra, Grazyna Hoser, Kanchan Kantekure, Darshan Roy, Barbara Gornicka, Margaret Nieborowska-Skorska, Elisabeth Bolton-Gillespie, Sabine Cerny-Reiterer, Markus Müschen, Peter Valent, Mariusz A. Wasik, Christine Richardson, Oliver Hantschel, Heiko van der Kuip, Tomasz Stoklosa, Tomasz Skorski
Journal: Blood
Blood (2016) 127 (17): 2131–2143.
https://doi.org/10.1182/blood-2015-11-681171
Published: 2016
Includes: Supplemental data
Journal Articles

Targeting BCR-ABL and JAK2 in Ph+ ALL

Oliver Hantschel
Journal: Blood
Blood (2015) 125 (9): 1362–1363.
https://doi.org/10.1182/blood-2014-12-617548
Published: 2015
Journal Articles

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Daniel W. Sherbenou, Oliver Hantschel, Ines Kaupe, Stephanie Willis, Thomas Bumm, Lalita P. Turaga, Thoralf Lange, Kim-Hien Dao, Richard D. Press, Brian J. Druker, Giulio Superti-Furga, Michael W. Deininger
Journal: Blood
Blood (2010) 116 (17): 3278–3285.
https://doi.org/10.1182/blood-2008-10-183665
Published: 2010
Includes: Supplemental data
Journal Articles

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

Uwe Rix, Oliver Hantschel, Gerhard Dürnberger, Lily L. Remsing Rix, Melanie Planyavsky, Nora V. Fernbach, Ines Kaupe, Keiryn L. Bennett, Peter Valent, Jacques Colinge, Thomas Köcher, Giulio Superti-Furga
Journal: Blood
Blood (2007) 110 (12): 4055–4063.
https://doi.org/10.1182/blood-2007-07-102061
Published: 2007
Includes: Supplemental data
Journal Articles

Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.

Oliver Hantschel, PhD, Uwe Rix, PhD, Tilmann Buerckstuemmer, PhD, Uwe Schmidt, PhD, Michael Kneidinger, MD, Keiryn L. Bennett, PhD, Ines Kaupe, BSc, Wilfried Ellmeier, PhD, Peter Valent, MD, Giulio Superti-Furga, PhD
Journal: Blood
Blood (2007) 110 (11): 4542.
https://doi.org/10.1182/blood.V110.11.4542.4542
Published: 2007
Journal Articles

A Subset of Chronic Myeloid Leukemia (CML) Patients on ABL Kinase Inhibitor Therapy Develop Point Mutations outside the BCR-ABL Kinase Domain That Decrease Drug Sensitivity and May Have a Role in Disease Progression.

Daniel W. Sherbenou, BA, Oliver Hantschel, PhD, Stephanie Willis, BS, Richard D. Press, MD, Brian J. Druker, MD, Giulio Superti-Furga, PhD, Michael W. Deininger, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 2188.
https://doi.org/10.1182/blood.V108.11.2188.2188
Published: 2006